Cochrane · intervention · CD013626
Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating patients with suspected or confirmed COVID‐19 infection
Burton, MJ, Clarkson, JE, Goulao, B, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
Full textEvery question was extracted from the full review (methods and results), not only its Summary of Findings table.
Questions
5
current version
GRADE rated
0
No studies
5
Included studies
0
as reported
No studies 5 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Review question
| Element | Planned (methods) | Found (results) |
|---|---|---|
| Population | Healthcare workers (HCWs) treating patients with suspected or confirmed COVID-19 infection; any healthcare setting | Insufficient data |
| Intervention | Any antimicrobial mouthwash and/or nasal spray (alone or in combination), at any concentration, delivered with any frequency or dosage to the HCWs, with or without the same intervention being given to the COVID-19 patients | Insufficient data |
| Comparison | No treatment; saline; water | Insufficient data |
| Outcomes | Primary: incidence of symptomatic or test-positive COVID-19 infection in HCWs; anosmia (or disturbance in sense of smell). Secondary: viral content of aerosol (if intervention administered to patients); other adverse events (changes in microbiome in oral cavity, nasal cavity, oro- or nasopharynx); other adverse events (allergy, irritation/burning of nasal, oral or oropharyngeal mucosa, long-term staining of mucous membranes or teeth, accidental ingestion) | Insufficient data |
| Study designs | Randomised controlled trials (RCTs); quasi-RCTs; non-randomised controlled trials; prospective cohort studies; retrospective cohort studies; cross-sectional studies; controlled before-and-after studies (no minimum duration) | Insufficient data |
| Timing | Primary outcomes assessed at a minimum of two weeks; no minimum follow-up for other outcomes | Insufficient data |
Search date: 2020-06. Databases: Cochrane Central Register of Controlled Trials (CENTRAL) (2020, Issue 6); Ovid MEDLINE; Ovid Embase; WHO COVID-19 Global literature on coronavirus disease; Cochrane COVID-19 Study Register
Questions and results
Any antimicrobial mouthwash and/or nasal spray (alone or in combination), at any concentration, delivered to healthcare workers, with or without the same intervention given to the patients with COVID-19 vs No treatment or saline or water
Population: Healthcare workers (HCWs) treating patients with suspected or confirmed COVID-19 infection
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Anosmia (or disturbance in sense of smell) Minimum 2 weeks | No data available (no included studies) | 0 studies | No studies |
Changes in microbiome in oral cavity, nasal cavity, oro- or nasopharynx | No data available (no included studies) | 0 studies | No studies |
Incidence of symptomatic or test-positive COVID-19 infection in HCWs Minimum 2 weeks | No data available (no included studies) | 0 studies | No studies |
Viral content of aerosol | No data available (no included studies) | 0 studies | No studies |
Other adverse events: allergy, irritation/burning of nasal, oral or oropharyngeal mucosa, long-term staining of mucous membranes or teeth, accidental ingestion | No data available (no included studies) | 0 studies | No studies |